Understanding the TIMI Risk Score for STEMI
The TIMI risk score for ST-elevation myocardial infarction (STEMI) is a bedside prognostic index that compresses several high-impact presentation features into a single additive total. Unlike the seven-item TIMI score used in unstable angina and non–ST-elevation acute coronary syndromes, the STEMI variant uses weighted components: some findings contribute more points than others. In clinical teaching, it is helpful to remember that the STEMI score was developed in populations where fibrinolytic eligibility and timing were central concerns, and that modern care often emphasizes primary percutaneous coronary intervention (PCI), antithrombotic refinement, and systems-of-care improvements. Even with those shifts, the score remains widely recognized as a structured way to communicate how multiple baseline hazards stack together at the moment of first assessment.
What problem the score is trying to solve
STEMI carries a meaningful risk of early death and complications, but that risk is not uniform. At presentation, clinicians already integrate age, hemodynamics, infarct territory, comorbidity burden, and logistics such as time-to-therapy. A formal score makes that integration explicit and reproducible: the same inputs yield the same total, which can support communication among team members, documentation, and educational comparisons across cases. The STEMI TIMI score is not a replacement for clinical judgment, invasive physiology, imaging, or protocol-driven reperfusion decisions; rather, it summarizes a specific set of routinely available bedside data into a compact prognostic signal.
Score structure: age plus weighted criteria
The total ranges from 0 to 14. Age contributes points in a mutually exclusive way: you assign points for one age band only (younger than 65 years, 65–74 years, or 75 years and older). The remaining items are independent toggles: if a criterion is present, its points are added; if absent, no points are added for that item. Several items are intentionally “heavy” (for example, hypotension and advanced age), reflecting their outsized association with early mortality in the original modeling framework.
Age bands
Younger than 65: baseline vulnerability from age alone is scored as zero in this system, although young patients can still accumulate substantial risk from hypotension, tachyarrhythmia, or shock. Ages 65–74: this band reflects intermediate physiologic reserve and higher prevalence of comorbidity and renal/ vascular disease burden than younger cohorts. Age 75 and older: this band receives the largest age-related increment, consistent with higher observed event rates in many acute MI datasets and greater sensitivity to hypotension, bleeding, and multi-organ stress.
Diabetes, hypertension, or angina (1 point)
This item captures chronic cardiovascular comorbidity and atherosclerotic disease context with a single point if any of the three is present. Diabetes mellitus often marks microvascular disease, adverse remodeling, and higher complexity after MI. Hypertension may correlate with long-standing LV hypertrophy, diastolic dysfunction, and cerebrovascular disease. A history of angina suggests prior ischemic burden and may align with multivessel disease or prior infarction. In practice, teams should document which elements are truly present rather than relying on incomplete histories, because this item is easy to under- or over-count when prior records are unavailable.
Systolic blood pressure below 100 mm Hg (3 points)
Hypotension at presentation is one of the strongest drivers in many acute MI risk models. Reduced perfusion pressure can reflect reduced cardiac output from extensive infarction, arrhythmia, valvular catastrophe, right ventricular involvement, hypovolemia, vasodilation, or sepsis-mimicking states. A low systolic blood pressure also interacts dangerously with pharmacologic reperfusion strategies and antithrombotic loads. Because this criterion contributes multiple points, it often moves the total score sharply upward even when other items are absent—mirroring how hemodynamic instability dominates early risk in real-world care.
Heart rate above 100 beats per minute (2 points)
Sinus tachycardia may be a compensatory response to pain, anxiety, fever, anemia, pulmonary embolism, or reduced stroke volume. In STEMI, persistent tachycardia may also indicate a hyperadrenergic state, ongoing ischemia, heart failure, or arrhythmia burden. The score treats tachycardia as a simple threshold because it is reliably measured and repeatedly associated with worse early outcomes in acute infarction cohorts. Clinicians should still interpret the number in context: transient pain-related tachycardia may mean something different than sustained tachycardia with cool extremities and oliguria.
Killip class II through IV (2 points)
The Killip classification stratifies acute MI patients by clinical evidence of heart failure and shock. Classes II–IV include pulmonary congestion, frank pulmonary edema, and cardiogenic shock patterns in the classic framing. This item awards points when the patient is not Killip class I (no heart failure signs). In charting, teams should align the checkbox with a deliberate assessment of rales, hypoxia, perfusion, and hypotension rather than informal impressions, because Killip misclassification can distort both the score and quality metrics.
Body weight under 67 kg (150 lb) (1 point)
Lower body weight can correlate with frailty, reduced cardiac reserve, higher relative drug exposure, and different bleeding risk profiles. In fibrinolytic-era development, weight also intertwined with dosing considerations and outcomes. If weight is unknown, some clinicians estimate carefully, recognizing that error propagates into both the score and medication dosing decisions; wherever possible, measured weight improves fidelity.
Anterior ST elevation or left bundle branch block (1 point)
Anterior territory infarcts often involve a larger myocardial jeopardy region and may be associated with higher rates of arrhythmia and pump failure compared with smaller or non-anterior patterns, though individual anatomy varies. New or presumed-new left bundle branch block can obscure ST-segment interpretation and may be associated with delayed recognition or broader myocardial injury in selected presentations. This item should be applied using the same ECG standards your institution uses for STEMI diagnosis and activation pathways.
Time from symptom onset to treatment beyond 4 hours (1 point)
Prolonged ischemic time is associated with larger infarcts, more necrosis, more electrical instability, and less myocardial salvage. The original conceptualization emphasized delay to fibrinolytic therapy; in contemporary systems, “treatment” may be interpreted according to local definitions (e.g., first device time for PCI, or first medical contact-to-balloon intervals). The score’s value here is to force explicit consideration of temporal risk: late presenters are not merely “eligible or not eligible” for therapy—they may remain physiologically sicker even after reperfusion.
Interpreting the total: from single number to graded risk
After summing age points and all applicable weighted items, the resulting integer is compared to published mortality estimates derived from the score’s development and validation experience. Lower totals align with very low short-term mortality estimates, while higher totals align with steeply rising estimates. In teaching, it can be useful to emphasize the gradient: small increments in score can correspond to materially different estimated event rates, especially in mid-to-high ranges where hemodynamic compromise and advanced age compound one another.
Many clinicians also group scores into broad bands (for example, lower, intermediate, and higher) as a communication shortcut. Bands are not a substitute for individualized decision-making, but they can help teams prioritize monitoring intensity, early escalation, and family discussions in busy environments.
How this calculator page is intended to be used
This page’s interactive tool is designed to mirror the canonical weighting: select one age band, then mark each additional criterion that is true at presentation. The displayed total should match a manual sum performed from the same inputs. The accompanying mortality estimates are presented as approximate trial-linked figures meant for orientation, not as precise individualized probabilities for a unique patient in a unique hospital system.
Important limitations and modern care context
Primary PCI networks, radial access, potent P2Y12 inhibition, statin intensity, and rapid reperfusion have changed observed outcomes compared with many older fibrinolytic-era cohorts. Comorbidity profiles have shifted as populations age and as chronic disease management improves in some domains while worsening in others. The TIMI STEMI score should therefore be interpreted as a structured risk signal anchored to its derivation era, then tempered with contemporary data, invasive findings, echocardiography, laboratory trends, and the patient’s goals of care.
The score also does not incorporate every variable that clinicians weigh seriously—examples may include cardiac arrest at presentation, refractory ventricular arrhythmias, renal dysfunction, hemoglobin, lactate, oxygen requirements, and detailed anatomical jeopardy scores. Those omissions are not failures of the bedside tool; they reflect the design goal of retaining a small, fast set of inputs available without specialized testing.
Documentation, communication, and safety culture
When teams adopt a scoring habit, the greatest clinical benefit often comes from shared mental models: the same terms for Killip class, the same threshold for hypotension, the same definition of treatment delay, and consistent ECG localization practices. If the score is recorded in the medical record, pairing it with a brief narrative (“hypotension with Killip II symptoms, anterior STE, late presentation”) preserves context and reduces the risk that a number is read in isolation later.
Finally, the score should never be used to delay emergent reperfusion when STEMI criteria are met, nor to justify withholding indicated therapies solely because a total is low. It is a prognostic adjunct, not a gatekeeper for time-critical interventions.